ENTYVIO (vedolizumab) Patient Assistance Program
- Clear & Transparent Pricing — Applying To Takeda Directly Is Always Free
- Paperwork, Documentation & Doctor-Coordination Handled For You
- Comprehensive Support: From Application To Entire Journey
- Annual Re-certification And Refills Management
- Guidance For Both IV Entyvio (Part B) And The Entyvio Pen (Part D)
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Entyvio (Vedolizumab) Is FDA-Approved For Moderate-To-Severe Ulcerative Colitis And Crohn’s Disease. Unlike TNF Blockers, It Is Gut-Selective — It Targets Inflammation In The Digestive Tract Without Broadly Suppressing The Immune System.
- Takeda’s Published List Price Is $10,108.70 Per 300 mg IV Vial; The Self-Injected Entyvio Pen Lists At $3,639.14 Per Pen (About $7,278 Per Month At Every-2-Week Maintenance). The Entyvio Patient Assistance Program Through EntyvioConnect Provides Medication Free To Qualifying Patients.
- Commercially Insured Patients Can Pay As Little As $0 Per Dose Through The EntyvioConnect Co-Pay Program, With Up To $20,000 Per Year In Support — One Of The Highest Published Copay Maximums In The Category.
- Entyvio Was Selected By Medicare In January 2026 For Drug Price Negotiation — In The First Cycle Ever To Include Part B Infused Drugs — With Negotiated Prices Taking Effect In 2028. No Biosimilar Exists Yet; The First Applications Reached The FDA In Mid-2026.
What Is Entyvio Prescription Assistance Program?
The Entyvio Patient Assistance Program is Takeda’s dedicated free-medication program for vedolizumab, administered through EntyvioConnect. It provides Entyvio at no cost to patients who are uninsured or whose insurance is insufficient, based on income criteria reviewed case by case — and Medicare patients who qualify are covered through the remainder of the calendar year. Applying directly (1-855-ENTYVIO / 1-855-368-9846) is always free. The hard part is everything around the application: eligibility verification, income documentation, GI-practice coordination, infusion-center or specialty-pharmacy logistics, prior-authorization records, denial appeals, and renewal deadlines — plus a decision unique to Entyvio: the IV infusion and the self-injected Pen are billed under completely different benefits, which changes both your out-of-pocket costs and which assistance applies. For a flat $69.95 per month, our Patient Advocates handle every step and route you correctly the first time.
Pharmacy Price Comparison
- Without assistance, Entyvio costs roughly $5,500–$6,500 per dose. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$6,300/dose | Save ~$6,230/dose |
| CVS Pharmacy | ~$6,500/dose | Save ~$6,430/dose |
| Walmart | ~$5,700/dose | Save ~$5,630/dose |
| Costco | ~$5,600/dose | Save ~$5,530/dose |
Specialty Pharmacy | ~$5,800/dose | Save ~$5,730/dose |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Entyvio Prescription Program?
The Entyvio Patient Assistance Program is free to apply for and provides medication at no cost if approved. Our $69.95/month service covers full advocacy — for patients who want an experienced team managing the process end-to-end, especially when weighing the IV-vs-Pen decision or facing prior denials.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Entyvio:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $5,500–$6,500/dose per month even with the best discoun
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Takeda reviews Entyvio assistance eligibility individually, based on insurance status and financial need. You will generally qualify if the following are true — and if your situation doesn’t fit neatly, contact AffordMyPrescriptions so we can review your case and determine if you qualify for Entyvio assistance:
- You Are A U.S. Citizen Or Legal Resident
- • You Have A Valid Entyvio Prescription From A Licensed U.S. Healthcare Provider
- • You Are Uninsured, Underinsured, Or Have No Access To Alternative Coverage
- • You Meet The Program’s Income Criteria For Your Household Size (Reviewed Case By Case)
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Entyvio:
Entyvio (vedolizumab) is a gut-selective humanized monoclonal antibody that blocks the α4β7 integrin — the “homing molecule” that inflammatory white blood cells use to enter the digestive tract. By blocking that entry route specifically, Entyvio calms gut inflammation without the body-wide immune suppression of TNF blockers.
How Entyvio Works:
In ulcerative colitis and Crohn’s disease, immune cells stream into the gut lining and sustain chronic inflammation. Those cells carry the α4β7 integrin, which docks with a protein (MAdCAM-1) expressed mainly on gut blood vessels. Entyvio blocks that docking, so inflammatory cells can’t home to the intestine. Because the mechanism is largely confined to the gut, Entyvio is often chosen for patients who need effective IBD control with a narrower systemic footprint.
Form and Use:
Treatment starts with 300 mg IV infusions at weeks 0, 2, and 6. For maintenance, patients continue IV every 8 weeks or switch to the Entyvio Pen — a 108 mg subcutaneous self-injection every 2 weeks, FDA-approved for ulcerative colitis maintenance in 2023 and Crohn’s in 2024. The choice matters financially: IV runs through your medical benefit (Part B for Medicare, with infusion-facility fees), while the Pen runs through your pharmacy benefit (Part D, where the $2,100 cap applies). We help patients and their GI teams weigh both.
Biosimilar Availability:
No vedolizumab biosimilar is approved in the U.S. as of 2026 — but the pipeline just opened: the first biosimilar applications were accepted for FDA review in mid-2026. Meanwhile, Medicare selected Entyvio in January 2026 for drug price negotiation, in the first cycle ever to include Part B infused drugs, with negotiated prices effective January 2028. Relief is coming for Medicare patients — but it is two budget years away, which is why assistance programs matter now.
Warnings:
Entyvio can cause serious infusion-related and hypersensitivity reactions, and infections including rare cases of progressive multifocal leukoencephalopathy (PML) have been reported with integrin-class drugs. Report new or worsening neurological symptoms, signs of liver problems (fatigue, jaundice), or persistent infections promptly. Patients should be current on vaccinations before starting.
FAQ (Frequently Asked Questions)
How Much Does Entyvio Cost Without Insurance?
Takeda’s published list price is $10,108.70 per 300 mg IV vial — before infusion-center fees — and $3,639.14 per Entyvio Pen (about $7,278 monthly at maintenance dosing). Eligible patients can receive Entyvio free through Takeda’s assistance program; our $69.95 monthly fee covers full advocacy and enrollment management.
What Makes Entyvio Different From Humira Or Remicade?
Entyvio is gut-selective: it blocks immune-cell entry into the digestive tract specifically, rather than neutralizing TNF throughout the body. For many IBD patients that means effective control with less systemic immune suppression — and it’s often the next step when TNF blockers fail or aren’t tolerated.
Does Medicare Cover Entyvio?
Yes — IV infusions under Part B (20% coinsurance after deductible; the $2,100 Part D cap does not apply, so a Medigap or Advantage plan’s out-of-pocket maximum is what protects you), and the self-injected Pen under Part D, where the $2,100 cap does apply. Same drug, very different cost exposure
Why Does Medicare Price Negotiation Matter For Entyvio?
In January 2026, CMS selected Entyvio among the first Part B drugs ever chosen for Medicare price negotiation. Negotiated prices take effect January 1, 2028, which should meaningfully cut what Part B patients owe in coinsurance. Until then, the assistance programs on this page are the bridge.
Can I Use The $0 Copay Card With Medicare?
No — the EntyvioConnect Co-Pay Program (up to $20,000/year) is commercial-insurance only. Medicare patients rely on supplemental coverage, the Part D cap for the Pen, or the assistance program if income-qualified.
Is There A Biosimilar For Entyvio?
Not yet — the first vedolizumab biosimilar applications reached the FDA in mid-2026, so approvals are likely years, not months, away. No lower-cost substitute exists today.
What If My Application Is Denied?
If denied, we explore alternatives — switching to a TNF biosimilar (adalimumab or infliximab biosimilars at much lower cost), Stelara biosimilar, Skyrizi, Omvoh, or another IBD biologic with its own PAP, the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Crohn’s & Colitis Foundation, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
Between Takeda’s free-medication program, a $20,000-a-year copay benefit, and Medicare price negotiation arriving in 2028, Entyvio patients have real options — the challenge is matching the right one to your insurance and your form of the drug. Check your eligibility today; the pre-qualification review is free, and if we can’t help you, you pay nothing.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.